Interv Akut Kardiol. 2010;9(3):136-140

Risk of developing contrast - induced neuropathy and possibilities of management

Bronislav Janek
Klinika kardiologie, IKEM, Praha

An administration of iodine contrast media could lead to contrast-induced nephropathy (CIN). The occurence of CIN in high-risk patients

is not negligible and CIN may worsen short-term and in some circumstances long-term prognosis. Risk factors od CIN, scoring system

and possibilities of prevention are reviewed in the article.

Keywords: nephropathy, contrast-induce nephropathy, risk factors, prevention

Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janek B. Risk of developing contrast - induced neuropathy and possibilities of management. Interv Akut Kardiol. 2010;9(3):136-140.
Download citation

References

  1. Maeder M, Klein M, Fehr T, et al. Contrast Nephropathy: Rewiev Focusing on Prevention. JACC 2004; 44: 1763-1771. Go to original source... Go to PubMed...
  2. Guitterez NV, Diaz A, Timmis GC, et al. Determinants of serum creatinin trajectory in acute contrrast nephropathy. J Interv Cardiol 2002; 15: 349-354. Go to original source... Go to PubMed...
  3. Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary in patients with chronic renal insufficiency. Am J Cardiol 2003; 91: 1157-1162. Go to original source... Go to PubMed...
  4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinin. Nephron 1976; 16: 31-41. Go to original source... Go to PubMed...
  5. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rater from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Am intern Med 1999; 130: 461-470. Go to original source... Go to PubMed...
  6. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors adn raltionship to mortality. Am J Med 1997; 103: 368-375. Go to original source... Go to PubMed...
  7. Freeman RV, O´Donel M, Share D, et al. Blue Cross-Blue Shield of Michigan Consortium (BMC2). Nephropathy requiring dialysis after percutaneous coronary intervention ant the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068-1073. Go to original source... Go to PubMed...
  8. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutanous coronary interventions: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-1399. Go to original source...
  9. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004; 94: 300-305. Go to original source... Go to PubMed...
  10. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the PRINCE study: prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol 1999; 33: 403-411. Go to original source... Go to PubMed...
  11. Rich MW, Crecelius CA. Incidence, risk factors and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age and older. A prospective study. Arch Intern Med 1990; 150: 1237-1242. Go to original source...
  12. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Cathet Cardiovasc Intervent 2001; 52: 409-416. Go to original source... Go to PubMed...
  13. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1,196 patients: A randomized trial: The Iohexol Cooperative study. Kidney Int. 1995; 47: 254-261. Go to original source... Go to PubMed...
  14. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxicity in high-risk patients study of iso-osmolar and low-osmolar nonionic contrast media study investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499. Go to original source... Go to PubMed...
  15. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: A randomized controlled trial. J Am Coll Cardiol 2006; 48: 924-930. Go to original source... Go to PubMed...
  16. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impared Patients (CARE) study: A randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007; 115: 3189-3196. Go to original source... Go to PubMed...
  17. Mehran R. ICON. A prospective, randomized, placebo-controlled trial of ioxaglate versus iodixanol in patients at increased risk for contrast nephropathy. Proceedings of Transcatheter Cardiovascular Therapeutics 2006; 3: 10.
  18. Heinrich MC, Haeberle L, Mueller V, et al. Nephrotoxicity of Iso-osmolar Iodixanol Compared with Nonionic Low-osmolar Contrast Media: Meta-analysis of Randomized Controlled Trials. Radiology 2009; 250: 68-86. Go to original source... Go to PubMed...
  19. Wessely R, Koppara T, Bradaric C, et al. Choice of Contrast Medium in Patients With Impaired Renal Function Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions. 2009; 2(5): 430-437. Go to original source... Go to PubMed...
  20. Rudnick MR, Davidson C, Laskey W, et al. Nephrotoxicity of iodixanol vs. ioversol in patients with chronic kidney disease: The Visipaque angiography/interventions with laboratory outcomes in renal insufficiency (VALOR) trial. Am Heart J 2008; 156(4): 776-782. Go to original source... Go to PubMed...
  21. Reiterová J. Prevence nefropatie indukované kontrastními látkami u nemocných s chronickým onemocněním ledvin. Interní Med 2009; 11(7 a 8): 324-326.
  22. Spargias K, Adreanides E, Eftihia D, et al. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunkction undergoing coronary angiography or intervention. Circulation 2009; 120: 1793-1799. Go to original source... Go to PubMed...
  23. Vodzinská A, Branny M, Indrák J, et al. Prevencia kontrastom indukovanej nefropatie u stredne rizikových pacientov v podminekach Kardiocentra Třinec. Interv Akut Kardiol 2009; 8(2): 70-73.
  24. Matějka J, Varvařovský I, Vojtíšek P, et al. Prevence kontrastem indukované nefropatie ve starší populaci s chronickým onemocněním ledvin. Interv Akut Kardiol 2008; 7(2): 50-53.
  25. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trail to assess the role of saline hydrationon the developement of contrast nephrotoxicity. Nephron Clin Pract 2003; 93: C29-C34. Go to original source... Go to PubMed...
  26. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004; 62: 1-7. Go to original source... Go to PubMed...
  27. Krasuki RA, Beard BM, Geoghagan JD, et al. Optimal timing of hydration to erace contrast-associated nephropathy: Tho OTHER-CAN study. J Invasive Cardiol 2003; 15: 699-702. Go to PubMed...
  28. Nikolsky E, Mehran R. Hydration protocols to reduce the incidence of contrast-induced nephropathy. J Invasive Cardiol 2008; 20: 527-538. Go to PubMed...
  29. Lee PT, Chou KJ, Liu CP, et al. Renal protection for coronary angiography in advanced ranal failure patients by prophylactis hemodialysis. A randomize controlled trial. J Am Coll Cardiol 2007; 50: 1015-1020. Go to original source... Go to PubMed...
  30. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349: 1333-1340. Go to original source... Go to PubMed...
  31. Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrastinduced nephropaqthy in high-risk patients. Am J Med 2006; 119: 155-162. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.